José María
López-Picazo González
Consultor Médico
Publications (80) José María López-Picazo González publications
2024
-
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial
The Lancet Oncology, Vol. 25, Núm. 5, pp. 588-602
2022
-
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis
Cancer Letters, Vol. 529, pp. 70-84
-
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity
The Journal of experimental medicine, Vol. 219, Núm. 12
2021
-
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial
Oral Oncology, Vol. 115
-
Paradigms on immunotherapy combinations with chemotherapy
Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367
2020
-
Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients
Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348
-
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade
Nature cancer, Vol. 1, Núm. 1, pp. 75-85
2019
-
Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies
TH Open
-
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
Clinical and Translational Oncology, Vol. 21, Núm. 9, pp. 1270-1279
-
Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience
Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 805-809
-
Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial
Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2825-2834
-
The dynamic use of EGFR mutation analysis in cell-free DNA as a follow-up biomarker during different treatment lines in non-small-cell lung cancer patients
Disease Markers, Vol. 2019
2018
-
Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience
Breast Journal, Vol. 24, Núm. 4, pp. 473-479
-
Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer
Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483
-
Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study
PLoS ONE, Vol. 13, Núm. 8
-
Targeted DNA sequencing for assessing clonality in multiple lung tumors: A new approach to an old dilemma
Lung Cancer, Vol. 122, pp. 120-123
2017
-
Endovascular treatment of malignant superior vena cava syndrome secondary to lung cancer
Hospital practice (1995), Vol. 45, Núm. 3, pp. 70-75
-
The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche
Cancer Letters, Vol. 402, pp. 43-51
2016
-
Bringing model-based prediction to oncology clinical practice: A review of Pharmacometrics principles and applications
Oncologist, Vol. 21, Núm. 2, pp. 220-232
-
Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value
Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694